Table 2.

Risk of first incident clinical fracture in relation to time on treatment with teriparatide

Type of fracture	Observational period (months)	Number of patientsa	Fracture rate per 100 patient-years	Patients with ≥ 1 fractureb, n (%)	Odds Ratio vs. 0–6 months (95% CI)c,d	p valued
All clinical fractures	0–6	3054	1.27	60 (2.0)	Reference group
	> 6–12	2410	0.73	29 (1.2)	0.62 (0.39–0.96)	0.0321
	> 12–18	2072	0.44	14 (0.7)	0.35 (0.20–0.63)	0.0004
	> 18–24	1616	0.55	11 (0.7)	0.39 (0.20–0.73)	0.0036
Clinical vertebral fractures	0–6	3054	0.12	27 (0.9)	Reference group
	> 6–12	2410	0.04	7 (0.3)	0.35 (0.15, 0.79)	0.0119
	> 12–18	2072	0.02	3 (0.1)	0.18 (0.05, 0.60)	0.0052
	> 18–24	1616	0.03	2 (0.1)	0.19 (0.04, 0.83)	0.0267
Clinical nonvertebral fractures	0–6	3054	1.83	35 (1.1)	Reference group
	> 6–12	2410	1.40	22 (0.9)	0.78 (0.46, 1.33)	0.3665
	> 12–18	2072	0.85	11 (0.5)	0.45 (0.23, 0.89)	0.0209
	> 18–24	1616	1.03	9 (0.6)	0.49 (0.24, 1.02)	0.0568

n number of patients with valid (non-missing or unknown) values

^aNumber of participants with information regarding the number of sustained fractures during the observational period

^bSome patients experienced fractures in more than one observational period

^cAdjusted logistic regression model by age, body mass index, ethnicity, geographic region, tobacco use, prior use of osteoporosis medications or patient support programme, and history of fragility fractures after age 40, glucocorticoid-induced osteoporosis, diabetes (type I or II) or number of falls in the past year

^dCompared with the 0 to 6-month period